- Open Access
Bi-directional exosome-driven intercommunication between the hepatic niche and cancer cells
© The Author(s). 2017
Received: 6 July 2017
Accepted: 6 November 2017
Published: 14 November 2017
Our understanding of the multiple roles exosomes play during tumor progression is still very poor and the contribution of the normal tissue derived exosomes in distant seeding and tumor outgrowth has also not been widely appreciated.
Using our all-human liver microphysiological system (MPS) platform as a model to closely recapitulate the early metastatic events, we isolated exosomes from both tumor cells and liver microenvironment.
We observed that while priming of the hepatic niche (HepN) with MDA-231 breast cancer derived exosomes facilitated seeding of the cancer cells in the liver, subsequent tumor outgrowth was diminished; this was consistent with increased entry into dormancy. We found that hepatic niche (HepN) derived exosomes contribute significantly to the exosome pool and are distinguished from cancer derived exosomes based on their size, protein and miRNA content. By Ingenuity Pathway Analysis (IPA) of the miRNA content of the HepN, MDA-231/HepN and MDA-231 cells we showed that the HepN derived exosomes affect the breast cancer cells by suppressing pathways involved in cancer cell proliferation and invasion. More importantly exposure of MDA-231 and MDA-468 cells to purified normal HepN derived exosomes, induced changes in the cells consistent with a Mesenchymal to Epithelial reverting Transition (MErT). miRNA arrays performed on MDA-231 treated with Hum Hep/NPC derived exosomes showed significant changes in the levels of a select number of miRNAs involved in epithelial cell differentiation and miRNAs, such as miR186, miR23a and miR205, from our top and bottom bins have previously been reported to regulate E-cadherin transcription and MErT induction in various cancer types. Consistently HepN derived exosome treatment of breast and prostate cancer lines lead to a transient induction of E-cadherin and ZO-1 at the protein level and a more epithelial-like morphology of the cells.
Collectively our data revealed a novel mechanism of regulation of the metastatic cascade, showing a well-orchestrated, timely controlled crosstalk between the cancer cells and the HepN and implicating for the first time the normal tissue/HepN derived exosomes in enabling seeding and entry into dormancy of the cancer cells at the metastatic site.
During her lifetime, one in eight women will be diagnosed with breast cancer and despite the multimodal therapeutic schemes available, metastatic disease remains the main cause of mortality. Over half of those that succumb will have overt liver metastases . Metastasis is a multistep process that requires detachment of the cancer cells from the local tumor, extravasation and survival in the blood circulation, followed by an ectopic survival and proliferation at a distant site. The initial step for cells to leave the primary tumor is the loss of epithelial cell–cell adhesions and subsequent acquisition of a more mesenchymal-like invasive phenotype, referred to as Epithelial–Mesenchymal Transition (EMT) , main hallmark of which is loss of E-cadherin, a calcium (Ca2+)-dependent transmembrane glycoprotein that mediates cell-cell cohesion. However, we and others have shown that while necessary for invasion, E-cadherin downregulation is reversed during the metastatic seeding [3–5] and that entry into dormancy relies on this cancer cell phenotypic plasticity through which highly dedifferentiated breast cancers appear more epithelial in the metastatic milieu [2, 6–8]. Our laboratory has focused on the development and use of an all-human liver microphysiological system (MPS) that uses fresh human hepatic tissue to recapitulate the hepatic niche (HepN) so as to study the steps of the metastatic seeding, tumor outgrowth and entry into dormancy of cancer cells as a model that closely mimics the process in vivo and allows the monitoring and immediate interactions between the cancer cells and the hepatic microenvironment [9–11].
How cancer cells communicate with their local and distant environment is undergoing a re-evaluation with the discovery that all cells release extracellular vesicles (EVs) to their surrounding milieu. EVs vary in size and function from apoptotic bodies (1000–5000 nm) to microvesicles (MVs 200–1000 nm) and exosomes (30-150 nm). Exosomes were first described in the early 1980s during reticulocyte maturation and were believed to be a form of “cellular waste disposal”. It took several decades for the scientific community to realize that the exosomes are critical to tissue homeostasis and master regulators of cell-to-cell communication [12, 13]. Contrary to the other EVs formation process, the biogenesis of exosomes is intricate and requires multiple levels of regulation, including the formation of late endosomes or multivesicular bodies (MVBs). MVB formation is primarily regulated by the endosomal sorting complexes required for transport (ESCRT) and during this stage, cytoplasmic RNA and proteins get incorporated into exosomes. Subsequently these MVBs fuse with the cell membrane and release exosomes to the extracellular space . All exosomes contain common proteins that serve as exosome markers during their isolation, including the tetraspanins CD9, CD81 and CD63, ESCRT associated proteins, like Alix and TSG101 and cytoplasmic proteins, such as Hsp70. However, the cell of origin and its physiologic state at any given time will also be reflected in the exosomal components, in addition to those structural ones noted above.
Through their cargo DNA, mRNA, miRNA, enzymes and soluble factors, exosomes can mediate various autocrine and paracrine signals and orchestrate intercellular communication. More specifically tumor derived exosomes or oncosomes  have largely been described as promoters of tumor progression and drivers of metastasis by generating a premetastatic milieu through fibroblast activation, immune suppression, extracellular matrix remodeling, enhanced vasculogenesis and/or drug resistance [13, 15–17]. Even though our understanding of the oncosomal contribution during tumor progression has advanced during the last decade, all our information is extracted from 2D cultures that do not closely mimic the metastatic cascade as it unfolds in the human body. Moreover, even though normal exosomes have been shown to be important for tissue homeostasis and wound healing, very little is known about the effects of normal tissue exosomes on tumor cells, particularly in reference to distant seeding and tumor outgrowth during cancer progression.
Herein, we studied the effect of exosomes in the metastatic seeding and proliferation of breast cancer cells to the liver. We showed that priming of the HepN with breast cancer derived exosomes results in significant enhancement of the cancer cell seeding in the liver, followed however by a suppressed tumor cell outgrowth in proliferation experiments. The same data was recapitulated in our Liver MPS that closely mimics the metastatic process. We hypothesized that the suppressed proliferation was due to the effect of the HepN derived exosomes on the colonizing breast cancer cells. We validated that the HepN significantly contributes to the exosome pool and that these exosomes, significantly different in size, protein and miRNA content, through miRNA regulation, activate pathways that suppress cancer cell proliferation and invasion. More importantly we show that treatment of MDA-231 and MDA-468 with purified normal HepN derived exosomes increases E-cadherin and ZO-1 protein expression levels in both breast cancer lines. Our data identifies a novel mechanism of regulation of the metastatic cascade, introducing the normal tissue/HepN derived exosomes as significant modulators of MErT during seeding and suppression of tumor growth once the breast cancer cells have reached the liver.
Cell lines and culture
Breast cancer cell lines, MDA-231 and MDA-468, were cultured in RPMI medium. MDA-231 obtained from ATCC were stably transfected with Red Fluorescent Protein (RFP) expressing vector as previously described . Prostate cancer line DU145 was cultured in DMEM medium. The melanoma line WM35 was maintained in MCDB153: L15 4:1 medium mixture with addition of 5% Fetal Bovine Serum (FBS), 5 μg/ml insulin and 2 mM CaCl2. The WM852 melanoma line was cultured in DMEM:L15 3:1 mixture with addition of 10% FBS . TPF16238, melanoma cells derived from patient sample, were kindly provided by Dr. Kirkwood and maintained in RPMI with 1 mM L-glutamine, 0,1 mM NEEA and 10 nM HEPES. All cells were incubated at 37 °C in 5% CO2, and supplemented with 1% v/v penicillin/streptomycin, and 10% v/v FBS, unless specified otherwise (Gibco, Life Technologies, Grand Island, NY, USA). The Trypan Blue exclusion method was used to assess cell viability. As FBS contains exosomes of bovine origin, all cell cultures were depleted of serum for 24 h prior to exosomes isolation as previously described by Théry et al. .
The primary human hepatocytes (Hep) and non-parenchymal cells (NPCs) were obtained from therapeutic partial hepatectomies for metastatic colorectal carcinoma or, more usually, benign diseases such as focal nodular hyperplasia and hemangiomas. The cells are available from the NIDDK-funded Liver Tissue and Cell Distribution System (LTCDS) with the procurement core directed by Dr. David Geller at the University of Pittsburgh and funded by the NIH (Contract #HHSN276201200017C). The livers are perfused and separate isolations of Hep and NPCs were provided to us, as previously described . We further process the NPC fraction (to eliminate contaminating debris, hepatocytes, and red blood cells) as previously reported .
Exosomes were purified from cell culture supernatants by ultracentrifugation as previously described . Briefly, FBS free culture medium was collected and centrifuged at 300×g for 10 min to remove whole cells. The supernatant was then centrifuged at 3,000×g for 20 min to remove dead cells and debris. This supernatant was centrifuged at 10,000×g for 30 min to further remove cell debris. This supernatant was then spun at 100,000×g for 70 min and the pellet was washed with excess PBS to remove contaminating proteins followed by a 70 min centrifugation at 100.000×g to obtain the exosome pellet.
Isolation of exosomes from the liver MPS was performed using the Total Exosome Isolation Reagent from cell culture media (Life Technologies); this method allowed for more efficient handling of smaller volumes from the MPS. After a 20 min centrifugation at 3,000×g the supernatant, containing the exosomes, was removed and combined with 1× volume of the Total Exosome Isolation Reagent and incubated overnight at 4 °C. The exosomes were harvested after a 60 min centrifugation step at 10,000×g. The exosome pellet was subsequently washed in Phosphate Buffered Saline (PBS) followed by a 70 min spin at 100.000×g. A bicinchoninic acid (BCA) protein assay kit (Pierce, Thermo Fisher, OH, USA) was used to determine the concentration of exosome proteins and performed as per the manufacturer’s instructions.
Transmission electron microscopy
5 μl of freshly isolated exosomes in PBS suspension were applied to copper mesh Formvar coated carbon stabilized grids. They were allowed to adsorb to the grid for 2-3 min and then were wicked off with filter paper. For negative staining of the exosomes, 1% Aqueous Uranyl Acetate (5-10 μl) was applied to the grid for 30 s, then wicked off with Whatman filter paper. Grids were allowed to thoroughly dry before viewing.
Exosome staining-functional assay
Freshly isolated exosomes were stained with the red lipophilic dye DiI (Thermo Fisher, OH, USA) which is incorporated in the outer exosome membrane. Exosomes were stained in the dark at room temperature in 1 μM DiI, then washed in PBS and centrifuged for 70 min at 100,000×g to remove the unincorporated dye. Pelleted exosomes were resuspended in PBS and added to the cells in culture.
Exosome RNA isolation, cDNA and miRNA analysis
After the last PBS wash the exosome pellet was resuspended in RLT buffer and total RNA isolation was performed using the RNeasy kit (Qiagen, Hilden, Germany). RNA concentration was measured using the NanoDrop2000 Spectrophotometer (yield range: 60-160 ng/μl). For miRNA analysis, the Cancer Focus microRNA PCR Panel, miRCURY LNA was used (Exiqon, Denmark) by following the manufacturer’s protocol, and using the ExiLENT SYBR® Green master mix. Prior to amplification RNA was converted to cDNA with the Universal cDNA Synthesis Kit II (Exiqon, Denmark).
Plasmids and reagents
The pCT-CD63-GFP vector was obtained from System Bioscience (SBI, Palo Alto, CA, USA) and MDA-231 RFP+ cells were transfected using Lipofectamine2000 (Life Technologies, Grand Island, NY, USA) using 2,5 μg of plasmid DNA.
Ex vivo liver MPS
The ex vivo Liver MPS is assembled as recommended by the manufacturer (CN Bio Innovations Ltd., Oxford, UK). Scaffolds for tissue growth are freshly coated with 1% rat tail collagen type I (BD Biosciences, Life Technologies, Grand Island, NY, USA) in PBS for 1 h at 37 °C and washed with PBS before placement in the system. Prior to seeding the system is primed with 1% Bovine Serum Albumin (BSA) at 37 °C, which is then replaced with William’s Medium E (Gibco, Life Technologies) supplemented with the Hepatocyte Thawing and Plating Supplement Pack (Life Technologies). To recapitulate physiologic conditions hepatocytes and NPCs are plated at a 1:1 ratio (6 × 105 cells per well) in the system. Hepatocytes are cultured for approximately 16 h in the plating William’s E medium, described above, and are subsequently changed to William’s E medium supplemented with the Hepatocyte Maintenance Supplement Pack (Life Technologies), prepared following the manufacturer’s instructions. The medium is exchanged completely every 48 h. On day 2 and day 3 the system is primed using cancer derived exosomes (20 μg/well/day) and on day 3 cancer cells are introduced into the formed liver tissue. For seeding into the Liver MPS, 500 MDA-231 RFP+ cells were trypsinized and neutralized in complete growth medium, centrifuged and resuspended in hepatocyte maintenance medium.
2D co-culture experiments
6 × 105 primary human hepatocytes were plated using William’s Medium E supplemented with the Hepatocyte Thawing and Plating Supplement Pack in a well of a 6-well plate coated with 1% rat tail collagen in PBS and were allowed to attach overnight. The following day the medium was changed to William’s Medium E supplemented with the Hepatocyte Maintenance Supplement Pack. On day 2 and day 3 the cultures received cancer derived exosomes (20 μg/well/day) for priming and on day 3, 500 RFP+ cancer cells were seeded onto the hepatocyte monolayers. For the transwell assay, after priming of the HepN on day 2 and day 3, 2 × 104 cells were plated on the transwell coculture inserts (Millipore).
Immunofluorescence microscopy/ cancer cell detection and enumeration
MDA-231 and MDA-468 breast cancer cells were seeded on coverslips precoated with 1% collagen and then fixed with 2% paraformaldehyde in PBS. Following cell permeabilization with 0.1% Triton X-100, non-specific epitopes were blocked with 2% BSA and the cells were incubated with primary antibody diluted in 0.5% BSA at 4 °C overnight. After 2 washes in 0.5% BSA, cells were stained with Alexa Fluor® 488 conjugated secondary antibody at room temperature for 1 h. DAPI was applied to stain the nucleus.
For the 2D co-culture experiments, cells were fixed on day 4 and day 7 with 2% paraformaldehyde in PBS for 1 h at 4 °C and then were visualized using an Olympus BX51 with a 4× (PlanApo NA.0.08) objective (Olympus America Inc.). Digital images were obtained on an Olympus CCD camera using the SPOT 5.2 image acquisition software. The level of RFP-expressing breast cancer cells was determined using the ImageJ software. Images from the entire scaffolds were inclusively thresholded and the RFP+ portion measured as a percentage of the total area.
Exosomes and cells were lysed using radioimmune precipitation assay (RIPA) buffer with phosphatase inhibitor mixture II, III (Sigma) and protease inhibitor mixture (BD Biosciences). Protein extracts, separated by SDS-PAGE and transferred onto PVDF membranes, were probed with antibodies against E-cadherin (BD Biosciences), ZO-1 (BD Biosciences), CD81 and CD63 (System Bioscience) or actin (Sigma). Proteins of interest were detected with HRP-conjugated secondary anti-mouse IgG antibody (Sigma, 1:10.000) and visualized with the Pierce ECL Western blotting substrate (Thermo Scientific, Rockford, IL), according to the provided protocol. The Exo-Check™ exosome antibody arrays were purchased from System Bioscience and performed as instructed by the manufacturer.
Cell cycle analysis
Samples were collected and fixed in 70% ethanol overnight at 4 °C. For cell cycle analysis, fixed cells were washed in PBS and treated with RNase for 20 min at 37 °C. 5 μg/mL of Propidium Iodide (PI) were added to each sample and analyzed by flow cytometry.
The pathway analysis for the miRNA data was done with the use of QIAGEN’s Ingenuity Pathway Analysis (QIAGEN Redwood City, https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/, IPA Winter Release 2014).
Statistical analysis for all experiments was performed with using Prism7 software (GraphPad, La Jolla, CA). An independent Student’s t-test was used to determine statistical differences between experimental and control values. P values <0.05 were considered statistically significant.
Isolation and identification of functional breast cancer exosomes (breast oncosomes)
Priming of the hepatic niche (HepN) with MDA-231 derived exosomes enhances the homing and seeding of the breast cancer cells to the “liver” in 2D co-culture experiments
To evaluate whether the breast cancer cells promote their homing to the metastatic site through exosomes, we established 2D transwell co-culture experiments. Hum Hep/NPCs were plated on the bottom of transwell plates and primed with MDA-231 freshly isolated exosomes for 48 h (20 μg/well, as quantified by BCA assay). Next, 20,000 MDA-231 RFP+ cells were plated on the insert of the transwell plate and were allowed to trans-migrate to the bottom compartment for another 48 h (Fig. 1e, upper panel). After quantification of the RFP+ cells (MDA-231) in the bottom compartment, we observed that oncosomal priming of the HepN resulted in a statistically significant homing of the breast cancer cells to the hepatocyte monolayer (Fig. 1e, lower panel). This indicates that the cancer derived exosomes promote breast cancer cell migration and attachment to the liver by establishing a permissive microenvironment. To decipher whether the oncosomal priming had an effect solely on the migratory potential of the cancer cells, and/or it also confined a survival advantage to the metastasizing cells, enhancing their seeding at the distant site, Hep/NPCs were allowed to attach overnight and were switched to culturing medium containing MDA-231 derived exosomes for 48 h. On day 3, 500 MDA-231 RFP+ breast cancer cells were introduced to the hepatocyte monolayer cultures and on day 4 the experiment was concluded and the percentage of RFP+ area was quantified (Fig 1f). A slightly larger RFP+ area was observed when the HepN was primed with the cancer exosomes; while significance was not attained in this experiment (see below for similar trends), the small increase was reproducible. This suggested that the cancer cells do indeed promote their own homing and attachment/ seeding to the distant site by using exosomes as a means to fertilize the soil for tumor cell dissemination. This is an important finding considering that survival in the new metastatic niche is the most rate-limiting step in the formation of macrometastases.
Priming of the HepN with MDA-231 derived exosomes promotes cancer cell seeding to the HepN, but results in significantly suppressed cancer cell proliferation in the liver MPS
We approached this in two ways as with the 2D adherence. First, to assess initial seeding/intercalation, Hum Hep/NPCs were plated on the Liver MPS platform and at days 2 and 3 the wells were primed with 20 μg/well of MDA-231 freshly isolated exosomes (Fig. 2b). On day 3, 500 MDA-231 RFP+ cells were introduced in the system and on day 4 the scaffolds were harvested and the RFP positive area was quantified (Fig. 2c); a representative field is also shown for the RFP fluorescence from the tumor cells (Fig 2d). Thus we are isolating the initial event of intravasation and survival. In the Liver MPS context that closely mimics the in vivo metastatic seeding process, the priming with MDA-231 oncosomes slightly enhanced the tumor cell seeding to the HepN, confirming our observations in the 2D co-culture system. The metastatic site colonization is a necessary step in tumor cell progression and dissemination in the human body and our data indicates that it can be mediated and enhanced by the cancer derived exosomes in a cell autonomous manner.
The second aspect was to determine the fate of the tumor cells in the metastatic environment. Interestingly however, when the breast cancer cells were allowed to proliferate within the Liver MPS for 15 days (Fig. 2e), the initial enhanced seeding we observed above, did not result in an increased breast cancer cell outgrowth. By extending our timeline to 15 days we allowed for the breast cancer cells to outgrow in the metastatic niche through interaction with neighboring cancer cells and surrounding hepatocytes and NPCs. At day 15 the RFP+ area was quantified to extrapolate information on the cancer cell proliferation and was found significantly larger in the wells that had never received oncosomal priming (Fig. 2f, g). This was not only observed in the context of the liver MPS, but the same suppression of tumor cell proliferation was recapitulated in Hep/NPCs 2D co-cultures (Fig. 1g) on day 7 of culture. These results show that the suppression in tumor growth is not due to factors inherent to the Liver MPS. Rather liver-derived signals released in the culture appear to drive this, suggesting a crosstalk between the freshly invading cancer cells that promote their homing and seeding to the liver through exosomes and the receiving hepatic microenvironment.
Differential exosome protein and miRNA profiles between the HepN, MDA-231 in the HepN and MDA-231 in 2D cultures, identify a novel contribution of the HepN to the cancer cells during metastatic outgrowth
The discrepancy between tumor cell seeding and tumor cell proliferation after oncosomal priming, prompted us to search for a potential cause. At this point it is unclear however, whether this decrease in the proliferation levels and tumor cell outgrowth could be attributed to the effect of cancer derived exosomes, on the metastasizing cancer cells through selection for less proliferative, more quiescent clones, and/or due to the interaction of the activated Hep/NPCs with the cancer cells with which they are now in close proximity. And despite the fact that the tumor derived exosomes have been extensively studied, little is known about the normal tissue (e.g. HepN) derived exosomes.
Exosome protein analysis was performed using an exosome specific antibody array, and showed that the protein expression pattern in the three groups (MDA-231 alone in 2D, MDA-231 + HepN in the Liver MPS and HepN alone in the Liver MPS) differed significantly (Fig. 3c). Even though for most of the proteins tested the expression levels in the exosomes of MDA-231 + HepN were distinct from the MDA-231 alone, these differences cannot be attributed to a mere additive contribution of the HepN derived exosomes in the pool of the total exosomes isolated from the MDA-231 + HepN sample. Along these lines, after normalization of all the samples to internal controls, proteins like FLOT1, EpCam, TSG101 and ANXA5 had a very similar expression pattern in the HepN and MDA-231 + HepN samples pointing to the direct contribution of the HepN to exosomes isolated. But other proteins like CD81, CD63 and ALIX showed a dramatic difference between the two groups and also differed significantly from the MDA-231 derived exosomes (Fig. 3d), hinting towards a HepN mediated cancer cell transformation. In accordance to these findings, comparing the exosome miRNA content of the HepN alone versus the HepN + MDA-231, the miRNA content of the latter did not faithfully follow the expression pattern of the HepN alone (Fig. 3e). [Relative levels of the miRNA are provided in Additional file 1: Figure S1.] Our data collectively showed that within the micrometastatic milieu the two exosome subgroups (normal and cancer) co-exist and co-operate to modify the genotypic and phenotypic characteristics of the metastasizing cancer cells during the metastatic tumor seeding and outgrowth phase.
The hepatic microenvironment suppresses tumor cell proliferation by exosome mediated signal transfer
To determine the effect of the HepN on cancer cell proliferation, after the initial cancer cell seeding, 2D co-culture experiments of HepN with melanoma cells (WM35, WM852 and TPF16238) were prepared. After the initial 48 h priming with the respective melanoma derived exosomes, the cancer cells were introduced to the hepatocyte monolayer on day 3 and were allowed to proliferate until day 7. On day 7 the cultures and supernatants were collected for cell cycle analysis using PI which revealed that in all three lines tested there was an increase in the cells that were in G0-G1 phase with a minimal change in the actively dividing cell populations (G2/M and S phase) (Additional file 1: Figure S3A). The decrease in the cells in SubG0 phase of the cell cycle indicates that after priming of the HepN with the cancer derived exosomes, the HepN signals to the cancer cells to help them avoid cell death during colonization to the liver and promotes a slow entry into the cell cycle and a proliferative arrest. This also shows that the effect of the HepN is not cell type specific and is not limited to the breast cancer cells. Exosomes purified from the HepN in the Liver MPS were analyzed for their miRNA content and even though no pathways were overall found suppressed or activated, there was a significant enrichment in miRNAs involved in cell cycle regulation and more specifically cancer cell arrest in G1 phase (Additional file 1: Figure S3B).
Purified HepN derived exosomes promote changes in the cancer cells consistent with a partial MErT
Our laboratory in previously published work has shown that MDA-231, which are negative for E-cadherin could be induced to re-express it by in vitro coculture with normal hepatocytes or following spontaneous metastasis to the lung in a mouse model [3, 8]. To investigate whether this effect could potentially be mediated by transfer of HepN derived exosomes to the cancer cells we treated MDA-231 and MDA-468 cancer cells with pure HepN derived exosomes. Using immunofluorescence we observed that the wells that had received HepN exosomes significantly upregulated the levels of E-cadherin. We were able to reproduce the induction of E-cadherin in both breast cancer lines and the prostate cancer line DU145 (Fig. 5e). The induction of E-cadherin was not accompanied by a significant decrease in vimentin levels or levels of mRNA for Twist, snail or slug (data not shown) but ZO-1 was upregulated in two of the three lines (Additional file 1: Figure S5). Changes in E-cadherin levels during MErT are driving changes in cell morphology from a mesenchymal to a more epithelial type, which was indeed the case for MDA-468 and DU145 (Fig. 5f). No changes were observed in the morphology of MDA-231 cells after HepN exosome treatment potentially due to increased autocrine downregulation.
Metastasis is a multistep complex process that despite having detrimental effects on the patient’s prognosis is inherently highly inefficient. In order to metastasize, the cancer cells need to undergo EMT to escape the primary tumor, extravasate into the circulation, avoid cell death due to lack of support from the surrounding cancer mass and extracellular matrix and subsequently colonize the distant site and resume proliferation. Many of these steps have been well studied and elucidated but recent advances have added a new level of complexity by identifying the cancer derived exosomes as critical shuttles for cell to cell communication, promoting tumor progression and increasing the efficacy of the metastatic cascade . Tumor derived exosomes mediate the transfer of oncogenic proteins and nucleic acids thus inducing a persistent and efficient modulation in the genotype and phenotype of the recipient cells [34–36]. Furthermore, they promote the recruitment and reprogramming of the tumor microenvironment to form a pro-tumorigenic soil, by establishing a positive feedback loop that shapes the ever-evolving tumor microenvironment and allows cancer cell seeding, proliferation and dissemination at distant sites [37–39]. However, the specific mechanisms through which healthy cells are triggered to release exosomes that promote or suppress the malignant behavior of cancer cells remain to be determined.
It must be noted that while we find classical exosomes, and our preparations appear mainly to consists of these as noted by classical shape and size on electron microscopy, the isolation techniques will enrich for all extracellular vesicles, both the larger blebs and the smaller exomeres. Herein we are not distinguishing between these, but rather using exosomes as the shorthand to encompass all such communicating vesicles.
Using our Liver MPS to closely reproduce the events of the metastatic cascade (ref BJC and LoC papers), we show that priming of the hepatic microenvironment with cancer derived exosomes promotes the seeding of breast cancer cells to the metastatic site. This is in agreement with published literature that shows the effect of the oncosomes in establishing a pre-metastatic niche [37–39]. However, more importantly we were able to recognize the significant contribution of the normal HepN derived exosomes to the exosomal pool during metastasis. It should be noted that the source of liver cells comes from donors undergoing partial hepatectomies for both benign and malignant diseases (though the cells are obtained from tissue distant from the pathology). While we do not note differences in MPS behavior between these sources, it is possible the pathology necessitating the partial hepatectomy influences the exosome profile and cargo even weeks later in the MPS. The HepN derived exosomes differ from the cancer derived exosomes in their size and their miRNA and protein cargo. These HepN derived exosomes are produced constantly but become more relevant once the cancer cells reach the liver microenvironment as they are now within range of interaction. It is also important to keep in mind that the cancer cells could potentially affect the normal cells through exosomes and soluble factors, modifying the exosome pool that the latter secrete. Herein we show that after the initial seeding to the liver, the cancer cells communicate with the HepN through exosomes and via miRNA transfer, the hepatic microenvironment suppresses cancer cell proliferation and promotes slow cell cycling.
These studies are performed ex vivo which entails both advantages and limitations. The all-human situation cannot be recapitulated in animal models, and thus select signals or miRNA that do not cross species may be approachable only with such a MPS. Further, the isolation of compartments and tissues, with rapid sampling of unmodified effluent is not readily achieved in vivo. Still, once specific molecules are identified as causally required, these may be targetable in animal models of spontaneous metastasis in future investigations.
Dormancy, defined as a more quiescent cell state, marked by slow proliferation and low metabolic activity has proven to be the main cause of treatment failures and cancer relapses. IPA of the miRNA profile of the MDA-231 in HepN shows a significant suppression in the pathways involved in cancer cell proliferation and invasion indicating that the interaction with the liver microenvironment results in alterations in the MDA-231 expression profile and changes in the cancer cell phenotype. To corroborate these findings we performed cell cycle analysis of 2D co-cultures and showed a delay of the cells in the G0-G1 phase and that the HepN derived exosomes are enriched in miRNAs involved in the regulation of G1 arrest. In the exosome protein array we observe a significant elevation of the exosomal marker CD81 in the MDA-231 cells in the HepN. The tetraspanin CD81 has been reported to be important regulator of cell fate in hematopoietic stem cells (HSC) and CD81 can drive proliferating HSC to quiescence . The HepN derived exosome-induced suppression of cancer cell proliferation is potentially a “tumor suppressive” mechanism that the normal tissue microenvironment at the distant site utilizes in order to maintain a steady state and minimize the changes that occur within it after the arrival and seeding of the cancer cells, however in the long term this could have detrimental effects for the patient since the cells can resume proliferation and outgrow at any time in the future. This observation has significant clinical implications considering that the cell cycle status often determines the cell’s response to chemotherapeutic agents. Future studies are required to further characterize the genotypic and phenotypic changes that occur and to further validate the dormant state of the cancer cells and their potentially acquired chemoresistance.
Furthermore we have previously shown that interaction of the breast cancer cells with the hepatocytes and NPCs in the liver leads to a re-expression of E-cadherin and a partial MErT [3, 8]. Our initial studies had found that neither conditioned media alone nor hepatocyte-derived matrix could trigger E-cadherin re-expression in this breast carcinoma line, though the combination of the two was noted to lead to a weak re-expression of E-cadherin . Herein we provide evidence that this effect on the breast cancer cells is exosome mediated and that treatment of breast and prostate cancer cells with purified normal HepN derived exosomes increases E-cadherin and ZO-1 protein expression levels and induces a more epithelial-like morphology. No significant changes were observed in the levels of the mesenchymal marker Vimentin suggesting a partial MErT. Our findings highlight the importance of the exosomes derived from the receptive microenvironment in the phenotypic plasticity of the cancer cells during tumor progression and the metastatic cascade. Through MErT and expression of adhesion molecules, the reversible phenotypic plasticity allows cancer cells to adapt to the foreign soil during ectopic organ colonization . Expression of the epithelial-marker and the cell adhesion molecule E-cadherin on breast cancer cells may be another mechanism to facilitate adhesion to hepatocytes .
The effects that we observe could largely be attributed to the exosomal transfer of miRNAs as these are master regulators. By comparing the miRNA content of MDA-231 that were exposed to HepN derived exosomes to MDA-231 we see that the miRNAs that are significantly upregulated or downregulated have been reported previously to regulate E-cadherin expression and MErT in various cancer types [28–36]. Additional testing of our miRNA hits in the top and bottom bins is essential for the identification of E-cadherin and MErT transcriptional regulators in our system since targeting with antagomirs could be a useful clinically applicable method to target the downstream pathways. Furthermore it is known that in most carcinomas, and namely in the MDA-231 breast cancer line, E-cadherin appears to be turned off at the translational level by promoter hypermethylation [42, 43]. Aberrations of DNA methylation have been inferred to play an important role during the initiation and progression of various cancers  and they could potentially play a critical role in our system as well since exosomes can act as epigenetic reprogrammers . Definitive assignment of critical role of likely multiple and overlapping miRNA will require both defining the cell types of origin and then targeted disruption, both of which lie beyond the scope of the present missive.
Our data collectively identifies a novel mechanism of regulation of the metastatic cascade, introducing the normal tissue/HepN derived exosomes as significant modulators of MErT during seeding and suppression of tumor growth once the breast cancer cells have reached the liver. The importance of the normal exosomes during the metastatic cascade has been widely underestimated, however we show that they become critical players during metastasis. We highlight the presence of a well-orchestrated exosome mediated bidirectional crosstalk between the cancer cells and the HepN that differentially regulates the steps of the metastatic cascade. The importance of the exosomes as signal shuttles stems from their newly established close proximity with the cancer cells. The concentration of exosomes in the blood are likely too dilute to strongly signal the liver from the primary site, and particularly in reverse. However, once the disseminated cell intravasates into the metastatic locale, the microenvironmental concentrations of these signals would be magnified, and likely more effective in altering cellular and tissue phenotypes. The present study posited such a directed bidirectional interaction. For the first time we introduce evidence that not only shows that cancer derived exosomes modify the premetastatic niche but the metastatic niche in turn also modulates the subsequent steps of the metastatic cascade determining the cancer cell fate.
These studies herein were supported by grants from NIH (UH3TR000496) and a VA Merit Award. ND was supported by an NIH Institutional Training Fellowship on Skin Biology and Cancer (T32CA175294) and CB by a Predoctoral Fellowship from NIH (F30CA199947).
We thank members of the Wells laboratory for the thoughtful discussions and suggestions.
ND isolated the exosomes, performed experiments and IPA analyses, and wrote the initial manuscript. AMC performed experiments with the MPS and performed IPA analyses. BM performed the experiments with the prostate cancer cells and validated the microRNA identification. CHB performed the coculture experiments. AW conceived of the study, provided resources and funding, and wrote the manuscript. All authors conceived of at least parts of the study, and planned and interpreted the experimental results. All authors provided editing. All authors read and approved the final version of the manuscript.
A Wells: Patent on LiverChip now being commercialized by CN Bio Innovations Ltd. All other authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Pickren J, Tsukada Y, Lane W. In: Weiss L, Gilbert L, editors. Liver metastasis. Boston, MA: G.K. Hall Medical Publishers; 1982.Google Scholar
- Yates C, Shepard CR, Papworth G, Dash A, Beer Stolz D, Tannenbaum S, Griffith L, Wells A. Novel three-dimensional organotypic liver bioreactor to directly visualize early events in metastatic progression. Adv Cancer Res. 2007;97:225–46.View ArticlePubMedGoogle Scholar
- Chao Y, Wu Q, Acquafondata M, Dhir R, Wells A. Partial mesenchymal to epithelial reverting transition in breast and prostate cancer metastases. Cancer Microenviron. 2012;5(1):19–28.View ArticlePubMedGoogle Scholar
- Gunasinghe NP, Wells A, Thompson EW, Hugo HJ. Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Rev. 2012;31(3–4):469–78.View ArticlePubMedGoogle Scholar
- Wells A, Yates C, Shepard CR. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis. 2008;25(6):621–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Bukholm IK, Nesland JM, Børresen-Dale AL. Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients. J Pathol. 2000;190(1):15–9.View ArticlePubMedGoogle Scholar
- Paul J. Kowalski, mark a Rubin, and Celina G Kleer. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res. 2003;5(6):R217–22.View ArticleGoogle Scholar
- Chao YL, Shepard CR, Wells A. Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer. 2010;9:179.View ArticlePubMedPubMed CentralGoogle Scholar
- Clark AM, Ma B, Taylor DL, Griffith L, Wells A. Liver metastases: microenvironments and ex-vivo models. Exp Biol Med (Maywood). 2016;241(15):1639–52.View ArticleGoogle Scholar
- Wheeler SE, Clark AM, Taylor DP, Young CL, Pillai VC, Stolz DB, Venkataramanan R, Lauffenburger D, Griffith L, Wells A. Spontaneous dormancy of metastatic breast cancer cells in an all human liver microphysiologic system. Br J Cancer. 2014;111(12):2342–50.View ArticlePubMedPubMed CentralGoogle Scholar
- Clark AM, Wheeler SE, Young CL, Stockdale L, Shepard Neiman J, Zhao W, Stolz DB, Venkataramanan R, Lauffenburger D, Griffithc L, Wells A. A liver microphysiological system of tumor cell dormancy and inflammatory responsiveness is affected by scaffold properties. Lab Chip. 2017;17:156–68.View ArticleGoogle Scholar
- Yu S, Cao H, Shen B, Feng J. Tumor-derived exosomes in cancer progression and treatment failure. Oncotarget. 2015;6(35):37151–68.View ArticlePubMedPubMed CentralGoogle Scholar
- Azmi AS, Bao B, Sarkar FH. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metas Rev. 2013;32:623–42.View ArticleGoogle Scholar
- Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl). 2013;91(4):431–7.View ArticleGoogle Scholar
- Syn N, Wang L, Sethi G, Thiery JP, Goh BC. Exosome-mediated metastasis: from epithelial-Mesenchymal transition to escape from Immunosurveillance. Trends Pharmacol Sci. 2016;37(7):606–17.View ArticlePubMedGoogle Scholar
- Zhang Y, Wang XF. A niche role for cancer exosomes in metastasis. Nat Cell Biol. 2015;17:709–11.View ArticlePubMedGoogle Scholar
- Abd-Elmageed ZY, Yang Y, Thomas R, Ranjan M, Mondal D, Moroz K, Fang Z, Rezk BM, Moparty K, Sikka SC, Sartor O, Abdel-Mageed AB. Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes. Stem Cells. 2014;32:983–97.View ArticlePubMedPubMed CentralGoogle Scholar
- Grahovac J, Becker D, Wells A. Melanoma cell invasiveness is promoted at least in part by the epidermal growth factor-like repeats of tenascin-C. J Invest Dermatol. 2013;133(1):210–20.View ArticlePubMedGoogle Scholar
- Théry C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006;Chapter 3:Unit 3.22.PubMedGoogle Scholar
- Hwa AJ, Fry RC, Sivaraman A, So PT, Samson LD, Stolz DB, Griffith LG. Rat liver sinusoidal endothelial cells survive without exogenous VEGF in 3D perfused co-cultures with hepatocytes. FASEB J. 2007;21(10):2564–79.View ArticlePubMedGoogle Scholar
- Wheeler SE, Borenstein JT, Clark AM, Ebrahimkhani M, Fox I, Griffith L, Inman W, Lauffenburger D, Nguyen T, Prantil-Baun R, Stolz D, Taylor D, Ulrich T, Venkateswaran C, Venkataramanan R, Wells A and C Young. All-human microphysical model of metastasis therapy. Stem Cell Research and Therapy. 2013;4:S11.Google Scholar
- Tian T, Wang Y, Wang H, Zhu Z, Xiao Z. Visualizing of the cellular uptake and intracellular trafficking of Exosomes by live-cell microscopy. J Cell Biochem. 2010;111:488–96.View ArticlePubMedGoogle Scholar
- Tian T, Zhu YL, Hu FH, Wang YY, Huang NP, Xiao ZD. Dynamics of exosome internalization and trafficking. J Cell Physiol. 2013;228(7):1487–95.View ArticlePubMedGoogle Scholar
- Chao Y, Wu Q, Shepard C, Wells A. Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance. Clin Exp Metastasis. 2012;29:39–50.View ArticlePubMedGoogle Scholar
- Mincy C, Eapen A. Exosome: potential biomarker for cancer. World J Res Rev (WJRR). 2016;2(4):01–4.Google Scholar
- Chevillet JR, Kang Q, Ruf IK, Briggs HA, Vojtech LN, Hughes SM, Cheng HH, Arroyo JD, Meredith EK, Gallichotte EN, Pogosova-Agadjanyan EL, Morrissey C, Stirewalt DL, Hladik F, Yu EY, Higano CS, Tewari M. Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc Natl Acad Sci (USA). 2014;111:14888–93.Google Scholar
- Hui X, Jiang J, Li Z, Ding L, Wang Y. MiR-186 acts as a tumor suppressor by targeting TWIST1/2 and regulating the epithelial-mesenchymal transition in glioblastoma multiforme. Int J Clin Exp Pathol. 2016;9(9):9706–14.Google Scholar
- Yao K, He L, Gan Y, Zeng Q, Dai Y, Tan J. MiR-186 suppresses the growth and metastasis of bladder cancer by targeting NSBP1. Diagn Pathol. 2015;10:146.View ArticlePubMedPubMed CentralGoogle Scholar
- Dong Y, Jin X, Sun Z, Zhao Y, Song X. MiR-186 inhibited migration of NSCLC via targeting cdc42 and effecting EMT process. Mol Cells. 2017;40(3):195–201.PubMedPubMed CentralGoogle Scholar
- Zhu X, Shen H, Yin X, Long L, Xie C, Liu Y, Hui L, Lin X, Fang Y, Cao Y, Xu Y, Li M, Xu W, Li Y. miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin. Oncogene. 2016;35(3):323–32.View ArticlePubMedGoogle Scholar
- Yanjiao M, Shixiu W, Ruping Z, Qinghua D. MiR-205 promotes proliferation, migration and invasion of nasopharyngeal carcinoma cells by activation of AKT signaling. J Int Med Res. 2016;44(2):231–40.View ArticleGoogle Scholar
- Li J, Yang S, Yan W, Yang J, Qin YJ, Lin XL, Xie RY, Wang SC, Jin W, Gao F, Shi JW, Zhao WT, Jia JS, Shen HF, Ke JR, Liu B, Zhao YQ, Huang WH, Yao KT, Li DJ, Xiao D. MicroRNA-19 triggers epithelial-Mesenchymal transition of lung cancer cells accompanied by growth inhibition. Lab Investig. 2015;95(9):1056–70.View ArticlePubMedGoogle Scholar
- Zhang X, Yuan X, Shi H, Wu L, Qian H, Xu W. Exosomes in cancer: small particle, big player. J Hematol Oncol. 2015;8:83.View ArticlePubMedPubMed CentralGoogle Scholar
- Melo SA, Sugimoto H, O'Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, Vitkin E, Perelman LT, Melo CA, Lucci A, Ivan C, Calin GA, Kalluri R. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014;26(5):707–21.View ArticlePubMedPubMed CentralGoogle Scholar
- Hood JL, San RS, Wickline SA. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 2011;71:3792–801.View ArticlePubMedGoogle Scholar
- Peinado H, Alečković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G, Ghajar C, Nitadori-Hoshino A, Hoffman C, Badal K, Garcia BA, Callahan MK, Yuan J, Martins VR, Skog J, Kaplan RN, Brady MS, Wolchok JD, Chapman PB, Kang Y, Bromberg J, Lyden D. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012;18(6):883–91.View ArticlePubMedPubMed CentralGoogle Scholar
- Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, Xiang J, Zhang T, Theilen TM, García-Santos G, Williams C, Ararso Y, Huang Y, Rodrigues G, Shen TL, Labori KJ, Lothe IM, Kure EH, Hernandez J, Doussot A, Ebbesen SH, Grandgenett PM, Hollingsworth MA, Jain M, Mallya K, Batra SK, Jarnagin WR, Schwartz RE, Matei I, Peinado H, Stanger BZ, Bromberg J, Lyden D. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol. 2015;17(6):816–26.View ArticlePubMedGoogle Scholar
- Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol. 2011;21(2):139–46.View ArticlePubMedGoogle Scholar
- Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438(7069):820–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Lin KK, Rossi L, Boles NC, Hall BE, George TC, Goodell MA. CD81 is essential for the re-entry of hematopoietic stem cells to quiescence following stress-induced proliferation via deactivation of the Akt pathway. PLoS Biol. 2011 Sep;9(9):e1001148.View ArticlePubMedPubMed CentralGoogle Scholar
- Glinskii OV, Huxley VH, Glinsky GV, Pienta KJ, Raz A, Glinsky VV. Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia. 2005;7:522–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415–28.View ArticlePubMedGoogle Scholar
- Strathdee G. Epigenetic versus genetic alterations in the inactivation of E-cadherin seminars. Cancer Biol Ther. 2002;12:373–9. Sumadi Lukman AnwarView ArticleGoogle Scholar
- Anwar SL, Lehmann U. DNA methylation, microRNAs, and their crosstalk as potential biomarkers in hepatocellular carcinoma. World J Gastroenterol. 2014 Jun 28;20(24):7894–913.View ArticlePubMedPubMed CentralGoogle Scholar
- Qian Z, Shen Q, Yang X, Qiu Y, Zhang W. The role of extracellular vesicles: an epigenetic view of the cancer microenvironment. Biomed Res Int. 2015;2015:649161.PubMedPubMed CentralGoogle Scholar